Onconetix
ONCO
4 hedge funds and large institutions have $479K invested in Onconetix in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less funds holding
Funds holding: 6 → 4 (-2)
74% less capital invested
Capital invested by funds: $1.82M → $479K (-$1.35M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$577K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$55.1K |
| 3 |
JP Morgan Chase
New York
|
-$7 |
ONCO Hedge Fund Activity: Q4 2023 in Review
4 of the 6,868 institutional investors tracked by Wall St. Rank reported a position in Onconetix (ONCO) for Q4 2023, worth a combined $479K — down 74% from $1.82M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ONCO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $577K sold.
- 4 institutional investors held Onconetix (ONCO) as of Q4 2023, down from 6 in Q3 2023.
- Funds reported $479K of Onconetix stock for Q4 2023, down 74% quarter-over-quarter.
- 0 funds opened new Onconetix positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest Onconetix seller in Q4 2023 was Armistice Capital, an estimated $577K sold.
Based on aggregated 13F filings for Q4 2023.